Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Samy Suissa PhD, FRSC, FCAHS

Samy Suissa PhD, FRSC, FCAHS

Distinguished James McGill Professor of Epidemiology, Biostatistics and Medicine, McGill University; Director, Centre for Clinical Epidemiology, Lady Davis Research Institute - Jewish General Hospital, Montreal, Quebec, Canada

Professor Suissa is a Distinguished James McGill Professor of Epidemiology and Biostatistics at McGill University, and Director of the Centre for Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Canada. He heads the Canadian Network for Observational Drug Effect Studies (CNODES).

Professor Suissa has conducted extensive research on the real-world effects of medications for different chronic diseases, including asthma, COPD and IPF. He specializes in research methods and authored over 550 peer-reviewed papers. 

He serves on the editorial boards of various scientific journals. He is a fellow of the Royal Society of Canada and of the Canadian Academy of Health Science, received the Distinguished Investigator award from the Canadian Institutes of Health Research and the FC Donders Professorship award from Universiteit Utrecht, Netherlands. 


S Suissa has attended scientific advisory committee meetings or consulted for AstraZeneca, Atara, Boehringer-Ingelheim, Merck, Novartis, Panalgo, Pfizer and Seqirus, and received speaking fees from AstraZeneca, Boehringer-Ingelheim and Novartis.